MétaCan
Menu
Back to cohort
Record W4414977427 · doi:10.1177/17588359251342241

A plain language summary publication of patients’ survival with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel

2025· review· en· W4414977427 on OpenAlexaff
Matthew A. Powell, Line Bjørge, Lyndsay Willmott, Z. Novák, Destin Black, Lucy Gilbert, Sudarshan Sharma, Giorgio Valabrega, Lisa M. Landrum, Martina Gropp‐Meier, Ashley Stuckey, Ingrid Boere, Michael A. Gold, Yakir Segev, Sarah Gill, Christine Gennigens, Alexandra Sebastianelli, Mark S. Shahin, Bhavana Pothuri, Bradley J. Monk, Joseph Buscema, Robert L. Coleman, Brian M. Slomovitz, Kari L. Ring, Thomas J. Herzog, Morad Marco Balas, Matthew J. Grimshaw, Shadi Stevens, Dominic W. Lai, Carolyn K. McCourt, Mansoor Raza Mirza

Bibliographic record

VenueTherapeutic Advances in Medical Oncology · 2025
Typereview
Languageen
FieldMedicine
TopicEndometrial and Cervical Cancer Treatments
Canadian institutionsUniversité LavalMcGill University Health Centre
FundersDaiichi Sankyo EuropeGenentechEisaiNateraSeagenIpsenClovis OncologyNRG OncologyIncyteLoxo OncologyToray IndustriesNovocureRegeneron PharmaceuticalsKaryopharm TherapeuticsMersana TherapeuticsBristol-Myers SquibbEli Lilly and CompanyAstraZenecaPharmaMarCelgenePfizer
KeywordsPlaceboEndometrial cancerPlain languageBiomarkerEnglish languageMEDLINE

Abstract

fetched live from OpenAlex

Summary What is the purpose of this PLS-P? The purpose of this plain language summary of publication is to help you understand recent findings from Part 1 of the RUBY study (full name ENGOT-EN6/GOG3031/RUBY trial). • Researchers sometimes study new combinations of already approved individual treatments to see if the combinations work well together and if they are safe to prescribe to patients. • In Part 1 of the RUBY study, the combination of dostarlimab with carboplatin-paclitaxel was investigated to see how well it worked for patients with primary advanced or recurrent endometrial cancer when compared with patients who were given placebo plus carboplatin-paclitaxel . • Patients in the RUBY study were divided into subgroups according to their biomarker status. This allowed researchers to see if biomarker status could help determine how well patients with specific biomarkers would respond to the combination of dostarlimab with carboplatin-paclitaxel. • This summary reports the results of the second data cut (the second time investigators looked at all of the data since the start of the study) of the RUBY study. At this time, researchers were looking specifically at how long patients lived and how safe the treatment was in patients who received dostarlimab with carboplatin-paclitaxel compared with those patients who received placebo plus carboplatin-paclitaxel .

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Other design · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.981
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0040.000
Bibliometrics0.0010.003
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.033
GPT teacher head0.396
Teacher spread0.364 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designOther design
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueTherapeutic Advances in Medical OncologySame topicEndometrial and Cervical Cancer TreatmentsFrench-language works237,207